Stockscreener 앱 받기
0.6105
3.65%
0.0215
시간 외 거래:
.62
0.0095
+1.56%
전일 마감가:
$0.589
열려 있는:
$0.58
하루 거래량:
62,935
Relative Volume:
0.40
시가총액:
$15.13M
수익:
$368.00K
순이익/손실:
$-9.54M
주가수익비율:
-1.2751
EPS:
-0.4788
순현금흐름:
$-9.47M
1주 성능:
-6.94%
1개월 성능:
+3.09%
6개월 성능:
-10.43%
1년 성능:
-38.95%
1일 변동 폭
$0.5701
$0.62
1주일 범위
$0.5701
$0.69
52주 변동 폭
$0.46
$1.55
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.6105 | 15.02M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Bioscience (LEXX) Completes Dosing in Key Animal Study - GuruFocus
Lexaria completes dosing study on next-generation GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria completes dosing study on next-generation GLP-1 drugs - Investing.com
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway - Weatherford Democrat
Weight-loss injection retatrutide tested as pill in Lexaria animal trial - Stock Titan
Whoosh Wellness Launches Physician-Guided Telehealth Platform Offering Oral-First Wellness Protocols and Prescribed Microdosing Programs - GlobeNewswire Inc.
Lexaria Bioscience to Attend BIO International Convention as Part of Expanded Business Development Push - citybuzz -
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program - Investing News Network
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program - TradingView
Lexaria drug platform sees record partner interest ahead of BIO - Stock Titan
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Lexaria Bioscience Finds its Niche in the Lucrative GLP-1 Market - The Globe and Mail
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Lexaria Gets Attention with GLP-1 Test on Deck - Bez Kabli
LEXX Should I Buy - Intellectia AI
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
MarketsMedicine Hat News - FinancialContent
TradingKey - TradingKey
lxrp_ex991.htm - SEC.gov
Lexaria Bioscience Releases Second Episode of Investor Video Series - Investing News Network
What Lexaria's CEO says is next for GLP-1 research in 2026 - Stock Titan
Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com India
Lexaria Updates Progress on Human Study #7 - Investing News Network
Lexaria advances semaglutide study with ethics review submission - Investing.com
Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - Investing News Network
Lexaria’s new video series zeroes in on a $75B GLP-1 market - Stock Titan
Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation - MEXC
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Th - GuruFocus
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Through 2026 - GuruFocus
Lexaria extends pharma partnership to evaluate GLP-1 technology By Investing.com - Investing.com South Africa
Lexaria extends pharma partnership to evaluate GLP-1 technology - Investing.com
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lexaria Bioscience Corp 주식 (LEXX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
2.60%
0.94%
자본화:
|
볼륨(24시간):